Home / Kallikrein 3/PSA / Human Kallikrein 3/PSA Quantikine ELISA Kit

Human Kallikrein 3/PSA Quantikine ELISA Kit

Catalog #: DKK300
17 Citations 1 Review Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
DKK300
Control Products Available
QC23: Quantikine Immunoassay Control Group 8
Human Kallikrein 3/PSA ELISA Cell Culture Supernate Standard Curve
3 Images
Product Details
Procedure
Citations (17)
FAQs
Supplemental Products
Reviews (1)
Summary Precision Recovery Linearity Data Examples Product Datasheets Preparation and Storage Background Related Research Areas

Human Kallikrein 3/PSA Quantikine ELISA Kit Summary

Assay Type
Solid Phase Sandwich ELISA
Format
96-well strip plate
Assay Length
4.5 hours
Sample Type & Volume Required Per Well
Cell Culture Supernates (50 uL), Serum (50 uL), EDTA Plasma (50 uL), Heparin Plasma (50 uL)
Sensitivity
0.069 ng/mL
Assay Range
0.9 - 60 ng/mL (Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma)
Specificity
Natural and recombinant human KLK3/PSA
Cross-reactivity
< 0.5% cross-reactivity observed with available related molecules.Cross-species reactivity not tested.
Interference
No significant interference observed with available related molecules.

Product Summary

The Quantikine Human KLK3/PSA Immunoassay is a 4.5 hour solid phase immunoassay designed to measure KLK3/PSA in cell culture supernates, serum, and plasma. It contains NS0-expressed recombinant human KLK3/PSA, and antibodies raised against the recombinant protein. Natural human KLK3/PSA showed dose-response curves that were parallel to the standard curves obtained using the recombinant Quantikine kit standards, indicating that this kit can be used to determine relative levels of natural human KLK3/PSA.

Precision

Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested on one plate to assess intra-assay precision
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in separate assays to assess inter-assay precision

Cell Culture Supernates

Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 40 40 40
Mean (pg/mL) 6.96 15.5 30 7.38 16.7 33
Standard Deviation 0.5 0.7 0.9 0.5 0.9 1.6
CV% 7.8 4.5 3 6.4 5.3 5

Serum, EDTA Plasma, Heparin Plasma

Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 40 40 40
Mean (pg/mL) 12.3 24.3 44.1 11.8 24.2 43.8
Standard Deviation 0.7 1.3 2 0.9 0.5 0.8
CV% 5.7 5.4 4.6 7.7 5.8 5.5

Recovery

The recovery of KLK3/PSA spiked to levels throughout the range of the assay in various matrices was evaluated.

Sample Type Average % Recovery Range %
Cell Culture Media (n=4) 99 93-105
EDTA Plasma (n=4) 100 93-103
Heparin Plasma (n=4) 101 97-109
Serum (n=4) 102 97-109

Linearity

To assess the linearity of the assay, samples containing and/or spiked with high concentrations of KLK3/PSA were serially diluted with the appropriate Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Human Kallikrein 3/PSA ELISA Linearity

Scientific Data

N/A Human Kallikrein 3/PSA ELISA Cell Culture Supernate Standard Curve View Larger

Human Kallikrein 3/PSA ELISA Cell Culture Supernate Standard Curve

N/A Human Kallikrein 3/PSA ELISA Serum/Plasma Standard Curve View Larger

Human Kallikrein 3/PSA ELISA Serum/Plasma Standard Curve

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Preparation and Storage

Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: Kallikrein 3/PSA

The human tissue kallikrein (KLK) gene family contains 15 members that play important roles in cancer. Notably, kallikrein-1, also known as tissue kallikrein, cleaves kininogen to release the vasoactive kinin peptide, bradykinin or lysyl-bradykinin. Kallikrein-3, called prostate specific antigen (PSA), is an established tumor marker that aids in the diagnosis, staging, and follow up of prostate cancer. Kallikrein-4 is specifically expressed in the prostate and over-expressed in prostate cancer. Kallikrein-5 is widely expressed but found at high levels in skin, breast, brain and testis; over-expression is an indicator of poor prognosis in ovarian cancer. Kallikrein-8 is expressed in the brain and is a novel marker of ovarian and cervical cancer.

Human plasma kallikrein, a serine protease, is synthesized in the liver and circulates in the plasma bound to high molecular weight (HMW) kininogen or as a free zymogen. Once activated by its physiological activator, coagulation factor XII, it displays endopeptidase activity towards peptide bonds after arginine (preferred) and lysine. It cleaves HMW kininogen, its major physiological substrate, to release the potent vasodilator peptide bradykinin. It is also able to cleave a number of inactive precursor proteins to generate active products, such as plasminogen and prourokinase.

Entrez Gene IDs:
354 (Human)
Alternate Names:
APS seminin; EC 3.4.21; EC 3.4.21.77; Gamma-seminoprotein; hK3; Kallikrein 3; kallikrein 3, (prostate specific antigen); Kallikrein-3; kallikrein-related peptidase 3; KLK2A1; KLK3; P-30 antigen; prostate specific antigen; prostate-specific antigen; PSA semenogelase; PSA; Semenogelase; Seminin
&#9888; WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.

Assay Procedure

Refer to the product for complete assay procedure.

Bring all reagents and samples to room temperature before use. It is recommended that all samples, standards, and controls be assayed in duplicate.
  1.   Prepare all reagents, standard dilutions, and samples as directed in the product insert.
  2.   Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.
    3. 100 µL Assay Diluent
  3.   Add 100 µL of the appropriate Assay Diluent to each well.
    4. 50 µL Standard, Control, or Sample
  4.   Add 50 µL of Standard, control, or sample to each well. Cover with a plate sealer, and incubate at room temperature for 2 hours.
  5.   Aspirate each well and wash, repeating the process 3 times for a total of 4 washes.
    6. 200 µL Conjugate
  6.   Add 200 µL of Conjugate to each well. Cover with a new plate sealer, and incubate at room temperature for 2 hours.
  7.   Aspirate and wash 4 times.
    8. 200 µL Substrate Solution
  8.   Add 200 µL Substrate Solution to each well. Incubate at room temperature for 30 minutes. PROTECT FROM LIGHT.
    9. 50 µL Stop Solution
  9.   Add 50 µL of Stop Solution to each well. Read at 450 nm within 30 minutes. Set wavelength correction to 540 nm or 570 nm.

Citations for Human Kallikrein 3/PSA Quantikine ELISA Kit

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

17 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model
    Authors: MI Suominen, M Knuuttila, CA Schatz, A Schlicker, J Vääräniemi, B Sjöholm, E Alhoniemi, B Haendler, D Mumberg, SM Käkönen, A Scholz
    International Journal of Molecular Sciences, 2023-01-22;24(3):.
    Species: Xenograft
    Sample Types: Serum
  2. (+)-JJ-74-138 is a novel non-competitive androgen receptor antagonist
    Authors: RN Cole, W Chen, LE Pascal, JB Nelson, P Wipf, Z Wang
    Molecular Cancer Therapeutics, 2022-04-01;0(0):.
    Species: Human
    Sample Types: Whole Cells
  3. Blocking GRP/GRP-R signaling decreases expression of androgen receptor splice variants and inhibits tumor growth in castration-resistant prostate cancer
    Authors: TC Case, A Merkel, M Ramirez-So, Q Liu, JA Sterling, R Jin
    Translational Oncology, 2021-08-27;14(11):101213.
    Species: Mouse
    Sample Types: Plasma
  4. Protein detection in blood with single-molecule imaging
    Authors: CP Mao, SC Wang, YP Su, SH Tseng, L He, AA Wu, RBS Roden, J Xiao, CF Hung
    Science Advances, 2021-08-11;7(33):.
    Species: Human
    Sample Types: Plasma
  5. Tumor characterization by ultrasound-release of multiple protein and microRNA biomarkers, preclinical and clinical evidence
    Authors: AL D'Souza, JR Chevillet, P Ghanouni, X Yan, M Tewari, SS Gambhir
    PLoS ONE, 2018-03-16;13(3):e0194268.
    Species: Human
    Sample Types: Cell Culture Supernates
  6. Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models
    Authors: MI Suominen, KM Fagerlund, JP Rissanen, YM Konkol, JP Morko, Z Peng, EJ Alhoniemi, SK Laine, E Corey, D Mumberg, K Ziegelbaue, SM Käkönen, J Halleen, RL Vessella, A Scholz
    Clin. Cancer Res., 2017-03-31;0(0):.
    Species: Mouse
    Sample Types: Serum
  7. Targeted nanoparticles encapsulating (-)-epigallocatechin-3-gallate for prostate cancer prevention and therapy
    Authors: V Sanna, CK Singh, R Jashari, VM Adhami, JC Chamcheu, I Rady, M Sechi, H Mukhtar, IA Siddiqui
    Sci Rep, 2017-02-01;7(0):41573.
    Species: Mouse
    Sample Types: Serum
  8. Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy
    Authors: Howard H Bailey
    Am J Clin Exp Urol, 2016-09-20;4(2):17-27.
    Species: Human
    Sample Types: Serum
  9. Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.
    Authors: Eswaraka J, Giddabasappa A, Han G, Lalwani K, Eisele K, Feng Z, Affolter T, Christensen J, Li G
    BMC Cancer, 2014-10-02;14(0):742.
    Species: Mouse
    Sample Types: Serum
  10. In vivo biomarker expression patterns are preserved in 3D cultures of Prostate Cancer.
    Authors: Windus L, Kiss D, Glover T, Avery V
    Exp Cell Res, 2012-07-27;318(19):2507-19.
    Species: Human
    Sample Types: Cell Culture Supernates
  11. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer.
    Authors: Colquhoun, A J, Venier, N A, Vandersluis, A D, Besla, R, Sugar, L M, Kiss, A, Fleshner, N E, Pollak, M, Klotz, L H, Venkateswaran, V
    Prostate Cancer Prostatic Dis, 2012-05-22;15(4):346-52.
    Species: Mouse
    Sample Types: Serum
  12. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.
    Authors: Squillace RM, Miller D, Wardwell SD, Wang F, Clackson T, Rivera VM
    Int. J. Oncol., 2012-05-18;41(2):425-32.
    Species: Human
    Sample Types: Cell Culture Supernates
  13. Sensitive plasma protein analysis by microparticle-based proximity ligation assays.
    Authors: Darmanis S, Nong RY, Hammond M, Gu J, Alderborn A, Vanelid J, Siegbahn A, Gustafsdottir S, Ericsson O, Landegren U, Kamali-Moghaddam M
    Mol. Cell Proteomics, 2009-11-27;9(2):327-35.
    Species: Human
    Sample Types: Plasma
  14. Transcriptional repression and inhibition of nuclear translocation of androgen receptor by diallyl trisulfide in human prostate cancer cells.
    Authors: Stan SD, Singh SV
    Clin. Cancer Res., 2009-07-21;15(15):4895-903.
    Species: Human
    Sample Types: Cell Culture Supernates
  15. D,L-Sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells.
    Authors: Kim SH, Singh SV
    Mol. Cancer Ther., 2009-07-07;8(7):1946-54.
    Species: Human
    Sample Types: Cell Culture Supernates
  16. Urine analysis and protein networking identify met as a marker of metastatic prostate cancer.
    Authors: Russo AL, Jedlicka K, Wernick M, McNally D, Kirk M, Sproull M, Smith S, Shankavaram U, Kaushal A, Figg WD, Dahut W, Citrin D, Bottaro DP, Albert PS, Tofilon PJ, Camphausen K
    Clin. Cancer Res., 2009-06-23;15(13):4292-8.
    Species: Human
    Sample Types: Cell Culture Supernates
  17. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway.
    Authors: Deep G, Oberlies NH, Kroll DJ, Agarwal R
    Oncogene, 2008-03-10;27(28):3986-98.
    Species: Human
    Sample Types: Cell Culture Supernates

FAQs

No product specific FAQs exist for this product, however you may

View all ELISA FAQs
Loading...

Reviews for Human Kallikrein 3/PSA Quantikine ELISA Kit

Average Rating: 5 (Based on 1 Review)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human Kallikrein 3/PSA Quantikine ELISA Kit?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human Kallikrein 3/PSA Quantikine ELISA Kit
By Anonymous on 06/09/2019
Sample Tested: EDTA Plasma
Human Kallikrein 3/PSA Quantikine ELISA Kit DKK300